New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 10 ir/ml (feline epithelium extract) - solution for injection - 10 ir/ml - active: allergen extracts 10 ir/ml (feline epithelium extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

Canada - English - Health Canada

greer laboratories inc - standardized kentucky blue/june grass pollen; standardized orchard grass pollen; standardized redtop grass pollen; standardized timothy grass pollen - solution - 10000unit; 10000unit; 10000unit; 10000unit - standardized kentucky blue/june grass pollen 10000unit; standardized orchard grass pollen 10000unit; standardized redtop grass pollen 10000unit; standardized timothy grass pollen 10000unit - allergenic extracts

Canada - English - Health Canada

greer laboratories inc - standardized kentucky blue/june grass pollen; standardized orchard grass pollen; standardized redtop grass pollen; standardized timothy grass pollen - solution - 100000unit; 100000unit; 100000unit; 100000unit - standardized kentucky blue/june grass pollen 100000unit; standardized orchard grass pollen 100000unit; standardized redtop grass pollen 100000unit; standardized timothy grass pollen 100000unit - allergenic extracts

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3) - ambrosia artemisiifolia pollen 20000 [pnu] in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 20000 [bau] in 1 ml - indicated use of allergenic extracts is for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to grass pollen and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants in situations where the offending allergen cannot be avoided. for previously untreated patients, prior to the initiation of therapy, clinical sensitivity to the standardized grass pollen extract should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. 10,000 bau/ml extracts are indicated for percutaneous testing. if negative, the 100,000 bau/ml dose may be used. availability of 10,000 and 100,000 bau/ml dosages facilitate safe

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - urochloa mutica pollen (unii: 3zo9ygz8zj) (urochloa mutica pollen - unii:3zo9ygz8zj) - urochloa mutica pollen 0.05 g in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 20000 [bau] in 1 ml - indicated use of allergenic extracts is for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to grass pollen and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants in situations where the offending allergen cannot be avoided. for previously untreated patients, prior to the initiation of therapy, clinical sensitivity to the standardized grass pollen extract should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. 10,000 bau/ml extracts are indicated for percutaneous testing. if negative, the 100,000 bau/ml dose may be used. availability of 10,000 and 100,000 bau/ml dosages facilitate safe

Canada - English - Health Canada

jubilant hollisterstier llc - pollen - solution - 40000unit - pollen 40000unit - allergenic extracts

United States - English - NLM (National Library of Medicine)

antigen laboratories, inc. - morella cerifera pollen (unii: lc8mev9s89) (morella cerifera pollen - unii:lc8mev9s89) - morella cerifera pollen 0.05 g in 1 ml - allergenic extract is used for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to the allergen, they experience allergic symptoms. confirmation is determined by skin testing. diagnostic use of allergenic extracts usually begins with direct skin testing. this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. do not administer in the presence of diseases characterized by bleeding diathesis. individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.

United States - English - NLM (National Library of Medicine)

antigen laboratories, inc. - beta vulgaris pollen (unii: w7nu4b5ciy) (beta vulgaris pollen - unii:w7nu4b5ciy) - beta vulgaris pollen 0.05 g in 1 ml - allergenic extract is used for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to the allergen, they experience allergic symptoms. confirmation is determined by skin testing. diagnostic use of allergenic extracts usually begins with direct skin testing. this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. do not administer in the presence of diseases characterized by bleeding diathesis. individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.